Dr. Jingsong Wang is currently the Head of China R&D and Head of Translational Medicine, Asia Pacific for Sanofi. Dr. Wang joined Sanofi from Bristol-Myers Squibb Co (BMS) where he served multiple roles with increasing responsibilities including Director of Discovery Medicine & Clinical Pharmacology (DMCP), Medical Lead for Orencia product renew team, Lead for global Exploratory Development Team (EDT) and Liaison to China R&D for DMCP.
Prior to BMS, Dr. Wang was at Wyeth (now part of Pfizer) where he served as Associate Director, and later as the Head for Translational Medicine and Biomarker Development in Inflammation and Rheumatologic Disease Area. Prior to that, Dr. Wang was at Brigham and Women’s Hospital and Harvard Medical School where he completed his clinical rheumatology fellowship and subsequently was an attending rheumatologist and faculty member. Dr. Wang has also completed a research fellowship at the Harvard School of Public Health.
Dr. Wang has published in numerous leading scientific journals and authored a number of textbook chapters related to inflammation and autoimmune diseases. Dr. Wang is board certified in rheumatology, a diplomate of American Board of Internal Medicine.
Jingsong’s academic appointments include visiting professorships in China, and he is an Adjunct Assistant Professor of Medicine and Radiology at University of Pennsylvania, and was an attending physician at the Hospital of The University of Pennsylvania. He is on the Research Grant Review Committee, National Natural Science Foundation of China (NSFC), and has served as a Scientific Grant Reviewer, Medical Research Council (MRC), National Institute for Health Research (NIHR), National Health Service (NHS), United Kingdom (UK) and as member of the expert panel for Biotechnology Industry Organization (BIO) congressional staff briefing on biotechnology and autoimmune diseases, Capitol Hill, Washington DC.
Jingsong has been active in the pharmaceutical communities